ClinicalTrials.gg

Program

zolacabtagene autoleucel

Also written as “CC-97540” and “BMS-986353”.

Its studies are mostly in Scleroderma, Systemic · Multiple Sclerosis · Lupus Erythematosus, Systemic · Lupus Nephritis · Anemia, Hemolytic, Autoimmune, led by Bristol-Myers Squibb.

Furthest: phase 3, since Jan 9, 20266 company-led studies, 5 open or runningNext primary completion: Jul 15, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bristol-Myers Squibb65 open or runningphase 3since Jan 9, 2026Jan 14, 2020Jul 15, 2027phase 1 · NCT06220201
  • Named in Bristol-Myers Squibb’s own pipeline as zola-cel, phase 3, as of Oct 29, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 14, 2020First study: phase 1 study in Lymphoma, Non-HodgkinFirst studyNCT04231747 · 24 enrolled · United States, Canada
  2. May 11, 2023Phase 1 study in Lupus Erythematosus, SystemicNCT05869955 · 270 enrolled · United States, Belgium, France and more
  3. Jan 4, 2024Phase 1 study in Multiple SclerosisNCT06220201 · 120 enrolled · United States, Belgium, France and more
  4. May 30, 2025Phase 2 study in Lupus Erythematosus, SystemicNCT07015983 · 89 enrolled · United States, Argentina, Austria and more
  5. Jan 9, 2026Phase 3 study in Scleroderma, SystemicPhase 3 reachedNCT07335562 · 92 planned · United States, Belgium, Canada and more
  6. May 18, 2026Phase 2 study in Anemia, Hemolytic, AutoimmuneNCT07603557 · 52 planned · United States, Denmark, Germany and more

Ahead

  1. Jul 15, 2027Primary completion: phase 1 study in Multiple SclerosisNCT06220201
  2. May 17, 2028Primary completion: phase 2 study in Lupus Erythematosus, SystemicNCT07015983
  3. Aug 29, 2028Primary completion: phase 1 study in Lupus Erythematosus, SystemicNCT05869955
  4. Nov 14, 2028Primary completion: phase 3 study in Scleroderma, SystemicNCT07335562

TargetBeta

“A preparation of autologous T-lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) CD19, with potential immunostimulating and antineoplastic activities. Upon administration, zolacabtagene autoleucel specifical…”NCIt, read by Claude
“A preparation of autologous T-lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) CD19, ”NCIt, by rule

Other programs on CD19

ProgramCompanyFurthest phaseStudies
blinatumomabruleAmgenphase 429
inebilizumabruleAmgenphase 419
Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012FAstraZenecaphase 312
axicabtagene ciloleucelruleGilead Sciencesphase 310
surovatamigAstraZenecaphase 310
lisocabtagene maraleucelruleBristol-Myers Squibbphase 310
Anti-CD19/CD3 Bispecific Antibody MK-1045Merckphase 38
obexelimabzenas-biopharma-usa-llcphase 37
Autologous Anti-CD19 CAR-T Cells CABA-201rulecabaletta-biophase 36
Autologous Anti-CD19/Anti-CD20 CAR-T Cells KITE-753ruleGilead Sciencesphase 32
rondecabtagene autoleucelrulelyell-immunopharma-incphase 32
rapcabtagene autoleucelNovartisphase 28

Studies

All 6 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07603557Anemia, Hemolytic, Autoimmune · United States, Denmark, Germany and more2Not yet recruitingMay 6, 203052
NCT07335562Scleroderma, Systemic · United States, Belgium, Canada and more3Not yet recruitingNov 14, 202892
NCT07015983Lupus Erythematosus, Systemic · United States, Argentina, Austria and more2Active, not recruitingMay 17, 202889
NCT06220201Multiple Sclerosis · United States, Belgium, France and more1Active, not recruitingJul 15, 2027120
NCT05869955Lupus Erythematosus, Systemic · United States, Belgium, France and more1Active, not recruitingAug 29, 2028270
NCT04231747Lymphoma, Non-Hodgkin · United States, Canada1CompletedFeb 1, 202424

How it is read

Names in the registry

  • “CC-97540”, 4 entries
  • “BMS-986353”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.